Synapse Research Institute, Maastricht, The Netherlands.
Rheumatology (Oxford). 2024 Feb 6;63(SI):SI64-SI71. doi: 10.1093/rheumatology/kead632.
In 2006, at a meeting in Sydney, Australia, consensus was reached by an international group of specialists to establish a number of serological criteria that identify patients with a history of thrombosis or pregnancy complications as having antiphospholipid syndrome (APS). These criteria were originally formulated for research purposes and to compare clinical trials in different centres. However, these same criteria are now generally used and accepted for the diagnosis and treatment of patients. The practice of using these criteria for direct patient care requires that these criteria are based on sound scientific evidence. Indeed, for all the autoantibodies that are officially included in the serological criteria, it has been shown that they induce thrombosis and fetal loss when infused into mice. There are also a number of additional autoantibodies that have been identified in these patients but for these antibodies there was not enough evidence to meet the official APS criteria in 2006. Seventeen years have now passed since the consensus meeting, therefore, this review examines whether additional studies performed with these 'non-criteria' autoantibodies have provided sufficient results to suggest the inclusion of these autoantibodies in the official serological criteria of APS.
2006 年，在澳大利亚悉尼举行的一次会议上，国际专家组达成共识，制定了一系列血清学标准，用于识别有血栓形成或妊娠并发症病史的患者是否患有抗磷脂综合征（APS）。这些标准最初是为了研究目的和比较不同中心的临床试验而制定的。然而，现在这些标准通常用于和被接受来诊断和治疗患者。使用这些标准直接为患者提供治疗服务的做法要求这些标准基于可靠的科学证据。事实上，对于所有正式纳入血清学标准的自身抗体，已经证明当将它们注入小鼠体内时，会诱导血栓形成和胎儿丢失。在这些患者中还发现了许多其他自身抗体，但对于这些抗体，2006 年没有足够的证据符合 APS 的正式标准。自共识会议以来已经过去了 17 年，因此，本综述检查了使用这些“非标准”自身抗体进行的额外研究是否提供了足够的结果，以建议将这些自身抗体纳入 APS 的正式血清学标准。
